Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia
Leuk Lymphoma
.
2024 Apr 22:1-2.
doi: 10.1080/10428194.2024.2341999.
Online ahead of print.
Authors
Caroline Fleck
1
,
Allison Karabinos
1
,
Allene Cook
1
,
Donald C Moore
1
,
Ryan Jacobs
2
Affiliations
1
Department of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
2
Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
PMID:
38646879
DOI:
10.1080/10428194.2024.2341999
No abstract available